CN1508259A - 重组人血小板源生长因子的发酵方法 - Google Patents
重组人血小板源生长因子的发酵方法 Download PDFInfo
- Publication number
- CN1508259A CN1508259A CNA021568391A CN02156839A CN1508259A CN 1508259 A CN1508259 A CN 1508259A CN A021568391 A CNA021568391 A CN A021568391A CN 02156839 A CN02156839 A CN 02156839A CN 1508259 A CN1508259 A CN 1508259A
- Authority
- CN
- China
- Prior art keywords
- rwj
- rhpdgf
- fermentative production
- hour
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000855 fermentation Methods 0.000 title claims description 13
- 230000004151 fermentation Effects 0.000 title claims description 13
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 title description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 37
- 108010081589 Becaplermin Proteins 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 230000001580 bacterial effect Effects 0.000 claims abstract description 7
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 12
- 102000013275 Somatomedins Human genes 0.000 claims description 12
- 238000012262 fermentative production Methods 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000011081 inoculation Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 230000003698 anagen phase Effects 0.000 claims description 3
- 235000003642 hunger Nutrition 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 108010084455 Zeocin Proteins 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 239000003102 growth factor Substances 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract 2
- 210000001772 blood platelet Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 208000008960 Diabetic foot Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical group CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 3
- 229960004787 becaplermin Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940116157 regranex Drugs 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010049927 Dry gangrene Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA021568391A CN1508259A (zh) | 2002-12-19 | 2002-12-19 | 重组人血小板源生长因子的发酵方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA021568391A CN1508259A (zh) | 2002-12-19 | 2002-12-19 | 重组人血小板源生长因子的发酵方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1508259A true CN1508259A (zh) | 2004-06-30 |
Family
ID=34236430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021568391A Pending CN1508259A (zh) | 2002-12-19 | 2002-12-19 | 重组人血小板源生长因子的发酵方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1508259A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103203023A (zh) * | 2005-09-26 | 2013-07-17 | 阿道恰公司 | 两亲聚合物-pdgf复合物 |
WO2015172752A3 (zh) * | 2014-05-16 | 2015-12-30 | 中国人民解放军军事医学科学院生物工程研究所 | 血小板衍生生长因子b突变体、其制备方法及用途 |
-
2002
- 2002-12-19 CN CNA021568391A patent/CN1508259A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103203023A (zh) * | 2005-09-26 | 2013-07-17 | 阿道恰公司 | 两亲聚合物-pdgf复合物 |
CN103203023B (zh) * | 2005-09-26 | 2016-06-01 | 阿道恰公司 | 两亲聚合物-pdgf复合物 |
WO2015172752A3 (zh) * | 2014-05-16 | 2015-12-30 | 中国人民解放军军事医学科学院生物工程研究所 | 血小板衍生生长因子b突变体、其制备方法及用途 |
US10450358B2 (en) | 2014-05-16 | 2019-10-22 | Institute Of Biotechnology Academy Of Military Medical Sciences P.L.A. China | Platelet-derived growth factor B mutant, preparation method therefor and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113005055B (zh) | 预防和/或治疗牙周炎的植物乳杆菌、其培养物及其制备和应用 | |
CN1188140C (zh) | 氧化性应激因子的水平降低 | |
CN115671032A (zh) | 一种含生物蛋白的医用抗hpv生物蛋白凝胶及其制备方法 | |
CN1508259A (zh) | 重组人血小板源生长因子的发酵方法 | |
CN113243446A (zh) | 一种谷糠蛋白提取物及其制备方法和应用 | |
CN108354922B (zh) | 一种用于治疗糖尿病慢性溃疡的药物制剂及其制备方法 | |
CN114099547B (zh) | 一种用于皮肤修复的干细胞外泌体制剂 | |
CN1025118C (zh) | 细胞生长刺激素的制造方法 | |
CN114949358A (zh) | 一种用于深部创面修复的复合材料及其制备方法 | |
CN115998962A (zh) | 一种组织粘附性复合水凝胶的合成方法及其绿色序列治疗种植体周围炎的应用 | |
CN113713176B (zh) | 一种水凝胶及其制备方法与应用 | |
CN103656751A (zh) | ADM-bFGF复合体及运用 | |
CN1296059C (zh) | 草分支杆菌免疫液 | |
CN1562392A (zh) | 采用生物反应器制备双层活性人工皮肤组织的方法 | |
CN111471738A (zh) | 一种鲨鱼硫酸软骨素的提取方法 | |
CN1623412A (zh) | 一种蚯蚓活性肽抗菌饲料原料及其生产方法 | |
CN117138028B (zh) | 一种含有表皮干细胞因子的组合物及其在糖尿病足修复中的应用 | |
CN110680949A (zh) | 一种基于母乳的创伤敷料的制备方法和应用 | |
CN101053346A (zh) | 一种益生菌发酵乳的制作方法 | |
CN110170007B (zh) | 抑制皮肤愈合过程色素沉积的组合物及其制备方法和应用 | |
CN115957368B (zh) | 一种皮肤创伤修复的细菌纤维素膜及其制备方法和应用 | |
CN1162161C (zh) | 金黄色葡萄球菌代谢产物凝胶剂及其制备方法 | |
US20240131222A1 (en) | Transdermal photocuring forming hydrogel with biological activity as well as a preparation method and an application thereof | |
CN117625454A (zh) | 一株有抗糖化抗衰功能的副干酪乳酪杆菌ccfm1355及其后生元 | |
CN1940075A (zh) | 携带人胸腺素β4基因的重组质粒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Xiaoying Document name: Notice of publication of application for patent for invention |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20051111 Pledge (preservation): Preservation |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Haibo Document name: Special business review memo Addressee: Zhang Haibo Document name: Deemed not to advise |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Qunqing Document name: Notification of termination of security procedure Addressee: Zhang Qunqing Document name: Notification of the application for patent for invention to go through the substantive examination procedure |
|
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING JINSAISHI BIOLOGICAL PHARMACEUTICAL TECHN DEVELOPMENT CO., LTD. Effective date: 20080523 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080523 Address after: Hedong District of Beichen Puji road in Tianjin No. 2 the modern Chinese medicine city post encoding: 300410 Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: Beijing, Haidian District, No. seven B Beijing Jinsaishi Biological Pharmaceutical Technology Development Co., Ltd. post encoding: 300410 Applicant before: Jinsaishi Bio-Pharmaceutical Technology Development Co., Ltd., Beijing |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20040630 |